

Statement of Advice

**daptomycin 350mg and 500mg powder for solution for injection or infusion
(Cubicin®)** **SMC No 1309/18**

Merck Sharp & Dohme Limited

12 January 2018

ADVICE: in the absence of a submission from the holder of the marketing authorisation

daptomycin (Cubicin®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of paediatric (1 to 17 years of age) patients with *Staphylococcus aureus* bacteraemia associated with complicated skin and soft-tissue infections.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman
Scottish Medicines Consortium